Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,970 JPY
Change Today -60.00 / -1.98%
Volume 116.2K
4552 On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
As of 2:00 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

jcr pharmaceuticals co ltd (4552) Snapshot

Open
¥3,000
Previous Close
¥3,030
Day High
¥3,005
Day Low
¥2,951
52 Week High
05/28/15 - ¥3,145
52 Week Low
01/26/15 - ¥2,173
Market Cap
96.3B
Average Volume 10 Days
76.3K
EPS TTM
¥52.84
Shares Outstanding
32.4M
EX-Date
09/28/15
P/E TM
56.2x
Dividend
¥20.00
Dividend Yield
0.62%
Current Stock Chart for JCR PHARMACEUTICALS CO LTD (4552)

Related News

No related news articles were found.

jcr pharmaceuticals co ltd (4552) Related Businessweek News

No Related Businessweek News Found

jcr pharmaceuticals co ltd (4552) Details

JCR Pharmaceuticals Co., Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products based on recombinant DNA technologies. Its product pipeline includes Follicle stimulating hormone, which is in preparation for Phase II/III clinical trials for the treatment of infertility; Epoetin Alfa, a Phase I clinical product for the treatment of renal anemia and predeposit autologous blood; and Darbopoietin Alfa, a preclinical stage product for use in renal anemia treatment. The company’s products under preparation for clinical trials include Iduronate-2-sulfatase and Alpha-galactosidase A for the treatment of lysosomal storage disease; and under preclinical stage comprise Glucocerebrosidase for the treatment of lysosomal storage disease. It also develops Human mesenchymal stem cells, which is in Phase II/III clinical trials for the treatment of graft-versus-host disease associated with hematopoietic stem cell transplantation. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is headquartered in Ashiya, Japan.

Founded in 1975

jcr pharmaceuticals co ltd (4552) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jcr pharmaceuticals co ltd (4552) Key Developments

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2015 Results on May 12, 2015

JCR Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2015 results on May 12, 2015

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2015 Results on Jan 30, 2015

JCR Pharmaceuticals Co., Ltd. announced that they will report Q3, 2015 results on Jan 30, 2015

JCR Pharmaceuticals Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2014; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2015; Announces Second Quarter-End Dividend for the Fiscal 2014; Provides Dividend Guidance for the Fiscal 2015

JCR Pharmaceuticals Co., Ltd. announced consolidated earnings results for the six months ended September 30, 2014. For the period, the company reported net sales of JPY 8,155 million against JPY 7,344 million a year ago. Operating income was JPY 455 million against JPY 667 million a year ago. Ordinary income was JPY 616 million against JPY 690 million a year ago. Net income was JPY 461 million or JPY 14.43 per diluted share against JPY 438 million or JPY 13.72 per diluted share a year ago. Income before income taxes was JPY 613,289 million against JPY 674,478,000 a year ago. Net cash provided by operating activities was JPY 739,072 million against JPY 2,509,888 million a year ago. For the year ending March 31, 2015, on consolidated basis, the company reported net sales of JPY 16,300 million, operating income of JPY 1,770 million, ordinary income of JPY 1,810 million and net income of JPY 1,300 million or JPY 40.90 per share. The company announced second quarter dividend of JPY 8.50 per share. For the fiscal 2015, the company expects to pay a year-end dividend of JPY 8.50 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4552:JP ¥2,970.00 JPY -60.00

4552 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4552.
View Industry Companies
 

Industry Analysis

4552

Industry Average

Valuation 4552 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JCR PHARMACEUTICALS CO LTD, please visit www.jcrpharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.